Abstract PD2-07: mRNA signatures predict response to durvalumab therapy in triple negative breast cancer (TNBC)– Results of the translational biomarker programme of the neoadjuvant double-blind placebo controlled GeparNuevo trial
S. Loibl, B. Sinn, T. Karn, M. Untch, D. Treue, H. Sinn, K. Weber, C. Hanusch, P. Fasching, J. Huober, D. Zahm, C. Jackisch, Jörg Thomalla, J. Blohmer, F. Marmé, F. Klauschen, K. Rhiem, B. Felder, G. Minckwitz, N. Burchardi, A. Schneeweiss, C. Denkert
Poster Discussion Abstracts